TY - JOUR
TI - Changes of circulating MicroRNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis
AU - Anastasilakis, A.D.
AU - Makras, P.
AU - Pikilidou, M.
AU - Tournis, S.
AU - Makris, K.
AU - Bisbinas, I.
AU - Tsave, O.
AU - Yovos, J.G.
AU - Yavropoulou, M.P.
JO - JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
PY - 2018
VL - 103
TODO - 3
SP - 1206-1213
PB - Oxford University Press
SN - 0021-972X
TODO - 10.1210/jc.2017-02406
TODO - circulating microRNA;  collagen type 1;  denosumab;  microRNA;  microRNA 124 3p;  microRNA 133a;  microRNA 21 5p;  microRNA 222 5p;  microRNA 23a 3p;  microRNA 24 3p;  microRNA 26a 5p;  microRNA 27a;  microRNA 33 3p;  microRNA 335 5p;  parathyroid hormone[1-34];  protein precursor;  unclassified drug;  biological marker;  bone density conservation agent;  circulating microRNA;  collagen type 1;  collagen type I trimeric cross-linked peptide;  denosumab;  DKK1 protein, human;  parathyroid hormone[1-34];  peptide;  peptide fragment;  procollagen;  procollagen Type I N-terminal peptide;  RUNX2 protein, human;  signal peptide;  transcription factor RUNX2, adult;  aged;  amino terminal sequence;  Article;  bone density;  bone metabolism;  bone turnover;  carboxy terminal sequence;  clinical trial;  correlational study;  drug effect;  drug efficacy;  female;  gene expression;  Greece;  human;  major clinical study;  observational study;  open study;  outpatient department;  postmenopause osteoporosis;  priority journal;  protein cross linking;  public hospital;  treatment response;  blood;  bone remodeling;  middle aged;  postmenopause osteoporosis;  treatment outcome;  very elderly, Aged;  Aged, 80 and over;  Biomarkers;  Bone Density;  Bone Density Conservation Agents;  Bone Remodeling;  Circulating MicroRNA;  Collagen Type I;  Core Binding Factor Alpha 1 Subunit;  Denosumab;  Female;  Humans;  Intercellular Signaling Peptides and Proteins;  Middle Aged;  Osteoporosis, Postmenopausal;  Peptide Fragments;  Peptides;  Procollagen;  Teriparatide;  Treatment Outcome
TODO - Context: Expression of microRNAs (miRs) related to bone metabolism in the serum may be affected by antiosteoporotic treatment. Objective: To investigate the effect of two antiosteoporotic agents with opposite effects on bone metabolism on miR expression profile in the serum. Design: Observational, open label, nonrandomized clinical trial. Setting: The outpatient clinics for Metabolic Bone Diseases of 424 General Military Hospital, Thessaloniki, Greece. Patients and Interventions: Postmenopausal women with low bone mass were treated with either teriparatide (TPTD; n = 30) or denosumab (n = 30) for 12 months. Main Outcome Measures: Changes in the serum expression of selected miRs linked to bone metabolism at 3 and 12 months of treatment. Secondary measurements: associations of measured miRs with changes in bone mineral density (BMD) at 12 months and the bone turnover markers (BTMs) C-terminal cross-linking telopeptide of type I collagen and procollagen type I N-terminal propeptide at 3 and 12 months. Results: We found significantly decreased relative expression of miR-33-3p at 3 months (P = 0.03) and of miR-133a at 12 months (P = 0.042) of TPTD treatment. BMD values at 12 months of TPTD treatment were significantly and inversely correlated with miR-124-3p expression at 3 months (P = 0.008). Relative expression of miR-24-3p and miR-27a was correlated with changes in BTMs during TPTD treatment and of miR-21-5p, miR-23a-3p, miR-26a-5p, miR-27a, miR-222-5p, and miR-335-5p with changes in BTMs during denosumab treatment. Conclusions: Circulating miRs are differentially affected by treatment with TPTD and denosumab. TPTD affects the relative expression of miRs related to the expression of RUNX-2 (miR-33) and DKK-1 gene (miR-133). Copyright © 2018 Endocrine Society.
ER -